The incidence of C. difficile infection has risen sharply over the last two decades. Today it is a leading cause of morbidity and mortality in hospital-acquired infections in the U.S. according to the U.S. Centers for Disease Control and Prevention (CDC).
XBiotech has recently launched an R&D program to develop a True Human™ antibody against C. difficile infection and has successfully identified donors with desired antibody reactivity. XBiotech believes this provides the first evidence that healthy humans possess natural anti-C. difficile antibodies, suggesting these antibodies work to clear C. difficile infection before it becomes clinically relevant.
XBiotech has also successfully established a platform for the efficient delivery of oral antibodies to the gut (in rodent models to date) and is working towards advancing a therapeutic antibody for oral delivery.